Human medicines European public assessment report (EPAR): Praxbind, idarucizumab, Date of authorisation: 20/11/2015, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, zilucoplan, Date of authorisation: 01/12/2023, Revision: 4, Status: Authorised

Savene

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Nulojix, belatacept, Date of authorisation: 17/06/2011, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Taltz, ixekizumab, Date of authorisation: 25/04/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Remsima, infliximab, Date of authorisation: 10/09/2013, Revision: 47, Status: Authorised

EMA business hours over King's Day and Labour Day, 27 April and 1 May

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 15, Status: Authorised